



Please Direct All Correspondence to Customer Number 20995

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Agger et al.
App. No : 10/563,731
Filed : January 6, 2006
For : ADJUVANT COMBINATIONS OF
LIPOSOMES AND MYCOBACTERIAL
LIPIDS FOR IMMUNIZATION
COMPOSITIONS AND VACCINES
Examiner : Oluwatosin Ogunbiyi
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 31, 2006

(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 10 references.
 - (X) Enclosing 10 references.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Agger et al.
App. No : 10/563,731
Filed : January 6, 2006
For : ADJUVANT COMBINATIONS OF
LIPOSOMES AND
MYCOBACTERIAL LIPIDS FOR
IMMUNIZATION COMPOSITIONS
AND VACCINES


Examiner : Oluwatosin Ogunbiyi
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 31, 2006

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing ten (10) references to be considered by the Examiner. Also enclosed are ten (10) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 31, 2006

By: 

Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/563,731
	Filing Date	January 6, 2006
	First Named Inventor	Else Marie Agger
	Art Unit	1645
SHEET 1 OF 1	Examiner	Oluwatosin Ogunbiyi
	Attorney Docket No.	PLOUG8.001APC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
-------------------	----------	---	--------------------------------	-------------------------------	--

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	1	WO 00/69458	11/23/2000	Statens Serum Institut		
	2	WO 02/074330 A2	09/26/2002	Stanford Rook Limited		
	3	WO 02/074333 A2	09/26/2002	Stanford Rook Limited		
	4	WO 03/011336 A2	02/13/2003	National Research Council of Canada		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	5	Dascher et al. "Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis." <i>International Immunology</i> ; 15(8):915-925 (2003).	
	6	Holten-Andersen et al. "Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines." <i>Infection and Immunity</i> ; 72(3):1608-1617 (2004).	
	7	Koike et al. "Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine." <i>Vaccine</i> ; 16(20):1982-1989 (1998).	
	8	Moura et al. "Down-Regulatory Effect <i>Mycobacterium leprae</i> Cell Wall Lipids on Phagocytosis, Oxidative Respiratory Bursts and Tumour Cell Killing by Mouse Bone Marrow Derived Macrophages." <i>Scand. J. Immunol.</i> ; 46:500-505 (1997).	
	9	Olsen et al. "Protection of Mice with a 9Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6." <i>Infection and Immunity</i> ; 69(5):2773-2778 (2001).	
	10	Saito et al. "Adjuvant Effect of Cord Factor, a Mycobacterial Lipid." <i>Infection and Immunity</i> ; 13(3):776-781 (1976).	

2437733 : 031306/CAP

Examiner Signature	/Nina Archie/	Date Considered	06/05/2008
--------------------	---------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./**